Summary & Overview
HCPCS Q2056: Ciltacabtagene Autoleucel CAR T-Cell Therapy
HCPCS Level II code Q2056 designates ciltacabtagene autoleucel as a single therapeutic dose of autologous BCMA-directed CAR T cells, including leukapheresis and dose preparation. This designation formalizes billing for a high-cost, high-complexity cellular immunotherapy used in treatment of BCMA-expressing hematologic cancers and matters nationally because it affects hospital and specialty center reimbursement, payer coverage policies, and patient access to advanced oncology care. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what this billing code represents clinically and operationally, which payers are commonly engaged, and what to expect in documentation and site-of-service considerations. The publication summarizes typical service settings (hospital inpatient or outpatient infusion centers with apheresis capability), outlines the included procedures (leukapheresis and dose preparation bundled per therapeutic dose), and clarifies where input data is unavailable. The content also highlights the implications for coverage policy development, prior authorization needs, and billing workflows for institutions administering autologous CAR T therapies. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q2056 describes ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose. This code represents a chimeric antigen receptor (CAR) T-cell therapy product manufactured from the patient’s own cells for targeted treatment of BCMA-expressing hematologic malignancies.
Service type: Cellular immunotherapy — autologous CAR T-cell therapy, inclusive of leukapheresis and product preparation.
Typical site of service: Hospital inpatient or outpatient infusion center with specialized cellular therapy and apheresis capabilities.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with relapsed/refractory multiple myeloma who has exhausted standard therapies presents for autologous BCMA-directed CAR T-cell therapy using ciltacabtagene autoleucel (Q2056). The multidisciplinary workflow includes hematology/oncology evaluation, eligibility confirmation, informed consent, baseline organ function testing (CBC, CMP, cardiac and pulmonary assessment), infectious disease screening, and collection of peripheral blood mononuclear cells via leukapheresis. Collected cells are sent to manufacturing for CAR transduction and expansion. Prior to lymphodepleting chemotherapy, the patient is admitted or observed in an outpatient infusion center for pre-infusion assessments and eligibility re-check. Lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) is administered per protocol. On the scheduled day, the thawed autologous CAR T-cell product is prepared and infused under close monitoring for infusion reactions. Post-infusion, the patient is observed for cytokine release syndrome and neurotoxicity with frequent vital signs, laboratory monitoring, and access to tocilizumab and corticosteroids per institutional algorithms. The typical site of service is an inpatient hematology/oncology unit or an outpatient specialized cellular therapy infusion suite within an academic cancer center or accredited cellular therapy program. Billing for the therapeutic dose of ciltacabtagene autoleucel is reported with Q2056, which includes leukapheresis and dose preparation procedures bundled per the HCPCS description.
Coding Specifications
| Modifier | Description | When to Use |
|---|